OSE Immunotherapeutics
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
OSE | PA
Overview
Corporate Details
- ISIN(s):
- FR0012127173 (+2 more)
- LEI:
- 969500HIUWVGY6NZSM05
- Country:
- France
- Address:
- 22 BOULEVARD BENONI GOULLIN, 44200 NANTES
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
OSE Immunotherapeutics is an integrated, clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's primary areas of focus are immuno-oncology (IO) and immuno-inflammation (I&I). Its research and development platform is centered on identifying specific targets to activate or regulate the immune response. OSE Immunotherapeutics advances its product candidates through early- to mid-stage clinical development before seeking partnerships for late-stage development and commercialization. The company maintains a pipeline of proprietary clinical assets aimed at addressing high unmet medical needs.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for OSE Immunotherapeutics and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-02 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Informations relatives au nombre total de droits de vote et d’actions composan…
|
French | 195.2 KB | |
| 2025-07-17 18:30 |
Regulatory News Service
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
|
English | 201.6 KB | |
| 2025-07-17 18:30 |
Report Publication Announcement
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
|
French | 212.2 KB | |
| 2025-06-20 19:30 |
Legal Proceedings Report
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene…
|
English | 226.5 KB | |
| 2025-06-20 19:30 |
Pre-Annual General Meeting Information
OSE Immunotherapeutics réaffirme son engagement à tenir une Assemblée Générale …
|
French | 204.2 KB | |
| 2025-06-11 18:30 |
Regulatory News Service
AJOURNEMENT DE L’ASSEMBLÉE GÉNÉRALE INITIALEMENT CONVOQUEE POUR LE 25 JUIN 2025
|
French | 201.6 KB | |
| 2025-06-11 18:30 |
Pre-Annual General Meeting Information
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025
|
English | 204.6 KB | |
| 2025-06-09 08:00 |
Pre-Annual General Meeting Information
MISE À JOUR DES MODALITÉS DE L’ASSEMBLÉE GÉNÉRALE
|
French | 178.6 KB | |
| 2025-06-09 08:00 |
Pre-Annual General Meeting Information
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
|
English | 184.3 KB | |
| 2025-06-05 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Informations relatives au nombre total de droits de vote et d’actions composan…
|
French | 196.4 KB | |
| 2025-06-04 08:00 |
Pre-Annual General Meeting Information
Ose Immunotherapeutics : Mise à disposition des documents préparatoires à l’Ass…
|
French | 174.9 KB | |
| 2025-06-04 08:00 |
Investor Presentation
OSE Immunotherapeutics renforce sa stratégie de croissance : Accélération des …
|
French | 791.9 KB | |
| 2025-06-04 08:00 |
Pre-Annual General Meeting Information
Ose Immunotherapeutics : Documents made available to the shareholders for the c…
|
English | 222.3 KB | |
| 2025-06-04 08:00 |
Business and Financial Review
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of…
|
English | 290.7 KB | |
| 2025-06-02 18:00 |
Regulatory News Service
OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Va…
|
English | 333.0 KB |
Automate Your Workflow. Get a real-time feed of all OSE Immunotherapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for OSE Immunotherapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-19 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,800.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-13 | N/A | Other | Sell | 6,369 | 45,879.09 EUR |
| 2024-06-03 | N/A | Other | Sell | 40,000 | 314,512.00 EUR |
